In addition, cancer cells expressing a myelodysplastic syndrome-associated splicing factor mutation (SRSF2<sup>P95H</sup>) are more sensitive to one of these compounds than those expressing the wild-type version of the protein. The gene discussed is SRSF2; the disease is myelodysplastic syndrome.